Loading dose of risankizumab for IBD is 600mg to 1.2g compared to 300mg inPsA!

Bone is the main AS target whereas soft tissue inflammation is the main target of psoriatic axial disease. HLA B27 particularly is a marker of osteitis at the site of enthesis, both severity and extent.

This study sparks my interest in #overlap #CTD.. it’s a starting point to examine the association of other non classical autoAb in #SLE. Hope you enjoy the reading. Monash University School of Clinical Sciences academic.oup.com/rheumatology/a…

Millions of Australians are affected by #arthritis and MSK conditions, yet access to affordable and accessible allied care remains inadequate. It's time to stand up for those living with chronic pain and limited mobility. Act now: arthritisaus.good.do/election25/Act…

Thrilled to share that I’ve been promoted to Professor. Grateful for the recognition, the opportunities to grow, and the brilliant colleagues who inspire me every day. Thank you Monash University and Monash Medicine, Nursing and Health Sciences for recognising the impact of my work and supporting the next chapter.

Lupus QD Clinic - Rhupus dsDNA+ SLE Plus CCP+ RA = Rhupus buff.ly/KCNNyf2

Pleased to see the final publication. Thank you for your leadership in bringing together our collective experience to help guide future clinicians in managing these rare manifestations.

As Lupus Awareness Month ends, a reminder: 💜 Listen to your body💜 Rest + move💜 Stay connected💜 Keep learning💜 Be kind to yourself Living well with lupus is possible—one step at a time. Check out lupusregistry.com/living-with-lu… CreakyJoints Australia Lupus Forum Musculoskeletal Health Australia #SLE

A retrospective VEXAS cohort study of 59 pts receiving 71 targeted Rx - 98%male, mean 71 yrs & 46% had myelodysplastic syndr. Treatments included tocilizumab(19), anakinra (13), azacitidine(13), baricitinib (11), & pred only (10). Best responses w/ azacitidine & tocilizumab

Thank you Musculoskeletal Health Australia for inviting me to write for our #lupus audience. CAR-T cell therapy shows promising potential—let’s hope larger studies confirm this and that it'll be more widely available. muscha.org/car-t-therapy-…

Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 Dr. John Cush buff.ly/lAS7D8u

Wonderful paper for all levels of clinicians. Improving Patients’ Treatment Expectations jamanetwork.com/journals/jama/…

1⃣‘Sjögren disease’ should replace ‘Sjögren syndrome’ 2⃣Acronym = SjD 3⃣‘Associated’ should be used in lieu of ‘secondary’ 4⃣ SjD = preferred terminology in clinical diagnosis 5⃣Differentiation btw primary & associated recommended for scientific studies rdcu.be/exhjU

lol. such a legend. Dr. Glaucomflecken Explains: Obinutuzumab in Lupus Nephritis (REGENCY) youtube.com/shorts/HMkZIpn… via YouTube

Proud to share Zhi Lim's latest review on promising new treatments for #Sjogrens! 🧬 How engineered regulatory T cell therapies could help rebalance the immune system and bring relief to patients? Ooi Labs Alberta Hoi MonashCID Monash University School of Clinical Sciences Monash Health sciencedirect.com/science/articl…

Dynamic time course of lab parameters from onset of #MAS to full blown disease. Note ferritin rise is quite late. #APLAR2025

Cxcl9 as surrogate for IFNg, IL-18, CD38+ CD8 lymphocytes are novel markers of #MAS, reflecting the activation of inflammasome, and T cell activation. #APLAR2025

Case study of sick MAS in sJIA used 12x pulses (1gx12 goodness!) oral CyA 5mg/kg then switch to IV CyA aiming for >800ng/ml, plus ultrafiltration. Just showed how sick/ desperate the treating Dr. lucky we now have Emapalumab #APLAR2025

Daratumumab targeting CD38 and pan-JAK inhibitor eg baricitinib/ tofacitinib maybe emerging therapies for #MAS #aplar2025

NEW COMMENT—Targeting B-cell activation to tackle both patient-reported and systemic disease outcomes in Sjögren's disease bit.ly/46xopoY